Stelara®

Active substance

Holder

Status

Closed

Indication

Treatment of moderate to severe active Crohn’s disease who have failed TNFα antagonists (infliximab/infliximab biosimilar, adalimumab) and the integrin inhibitor vedolizumab, or who are intolerant to, or have a contraindication to these treatments

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/09/2017